Welcome to CRCPress.com! We have customized the Taylor & Francis India website to host CRC Press titles. Please choose www.TandFIndia.com to get the following benefits:
South Asia Editions of CRC Press titles with INR prices
Multiple options to purchase locally
All CRC Press products available
Your CRC Press login credentials will work on TandFIndia.com
Garland Science Website Announcement
The Garland Science website is no longer available to access and you have been automatically redirected to CRCPress.com.
All instructor resources are now available on our Instructor Hub. Your GarlandScience.com instructor credentials will not grant access to the Hub, but existing and new users may request access here.
The student resources previously accessed via GarlandScience.com are no longer available to existing or new users.
Please accept our apologies for any inconvenience this may cause.
Exclusive web offer for individuals. Print titles only. Terms & Conditions may apply.
Given the increased attention by clinicians, researchers and the pharmaceutical industry to the management and treatment of dementia not only in the elderly but also in increasingly younger populations, the demands for effective evidence-based pharmaceutical control of dementia and quantitative assessment of outcomes have increased. Since some first steps in the early 1960's to the controversial landmark paper of Summers and colleagues, to the most recent trials, it is clear both that much progress has been made, and that much remains to be done. This book is written to take stock of what is now usefully known, and to speculate on directions for the future.
Table of Contents
Introduction. The History of Therapeutic Trials in Dementia. Therapeutic Strategies. Treatment Hypotheses. Clinical Trial Designs & Selection of Primary vs.Secondary Endpoints. Qualitative Analyses of Disease Treatment Effects. Inclusion and Exclusion Criteria. Global Outcomes. Cognitive Outcomes. Functional Outcomes. Behavioral Outcomes In Trials Of Cognitive Agents. Quality of Life Outcomes. Caregiver Burden Outcomes. Neuroimaging Outcomes. Additional Lessons From Trials in Vascular Dementia. Additional Lessons From Trials In Dementia With Lewy Bodies. Lessons From Trials To Prevent Dementia. Herbal Treatments for Dementia. Lessons from Trials of Psychoactive Compounds in Alzheimer's Disease. Lessons from Non-Pharmacologic and Psychosocial Interventions for Patients with Dementia. Lessons from Psychosocial Interventions Aimed at Caregivers of People with Dementia. Lessons from Trials in Mild Cognitive Impairment. Pharmacoeconomic Outcomes. Executive Dysfunction in Dementia. Ethical Issues. Conclusions.
"…a thorough and thoughtful examination of a complex area….a milestone in describing the playing field upon which drug trials of Alzheimer's disease should be conducted. It is a testament to how all the measures used to diagnose Alzheimer's disease do not equally gauge the progression of the disease. Alzheimer's disease is not monolithic, but varies greatly from stage to stage. This book promotes new ways of approaching this aspect of the disease." -Doody's Reviews
CPD consists of any educational activity which helps to maintain and develop knowledge, problem-solving, and technical skills with the aim to provide better health care through higher standards. It could be through conference attendance, group discussion or directed reading to name just a few examples.
Use certain CRC Press medical books to get your CPD points up for revalidation. We provide a free online form to document your learning and a certificate for your records.